The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-11 and is reviewed periodically as new material appears.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, monoclonal antibodies, and living medicines used in cell therapy. Biopharmaceuticals can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine. Terminology surrounding biopharmaceuticals varies between groups and entities, with different terms referring to different subsets of therapeutics within the general biopharmaceutical category. The term biologics is often used more restrictively to mean biopharmaceuticals that are produced using recombinant DNA technology. Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to engineered macromolecular products like protein- and nucleic acid-based drugs, distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source. Biopharmaceutics is pharmaceutics that works with biopharmaceuticals. Biopharmacology is the branch of pharmacology that studies biopharmaceuticals.
(2026) report evidence from the study of carbon and oxygen stable isotope compositions of mammal fossils from the Pinturas Formation (Argentina) indicative of presence of a diverse range of habitats in Patagonia during the Miocene, and interpret the diversity of the primate assemblage from the studied formation as likely linked to habitat diversity. Cooke et al. (2026) report the first discovery of mandibular remains of Stirtonia victoriae from the La Victoria Formation (Colombia), and interpret their anatomy as indicative of leaf-eating adaptations of the studied monkey. Urciuoli et al. (2026) determine the phylogenetic relationships of early members of Catarrhini on the basis of the study of the semicircular canal and vestibule shape in Saadanius, Pliobates, Ekembo and Victoriapithecus, interpret Saadanius as most likely to be a stem catarrhine that evolved ossified tubular ectotympanic independently from crown catarrhines, and interpret pliopithecoids as most likely to be stem catarrhines closer to the crown group than Saadanius. Arias-Martorell et al. (2026) report evidence of similarities of shape of the radial head of Pliobates cataloniae and extant apes, and interpret Pliobates as better adapted to climbing than to behaviors involving forelimb-dominated suspension. Arias-Martorell et al. (2026) compare the shape of the distal part of the humerus of Pliobates cataloniae and other extinct and extant simians, and interpret Pliobates as unlikely to perform acrobatic suspensory behaviors seen in extant gibbons.
In the mid-19th century, oil wells developed quickly in various parts of the world, though the title of the "first oil well" depends on the criteria. In 1846, a group of Russian Imperial engineers directed by Major Alexeyev of the Bakinskii Corps of Mining Engineers accidentally struck oil while hand-drilling with a primitive percussion rig in Bibi-Heybat, near Baku (now Azerbaijan), though they were not specifically searching for oil. In 1853, Ignacy Łukasiewicz, who discovered how to distill kerosene from seep crude oil and invented the modern kerosene lamp, hand-dug the first intentional well for commercial oil extraction in Bóbrka, Poland, to supply fuel for lighting (still operational as of 2025). A hand-dug well and another refinery followed in 1857 near Ploiești, Romania. Romania (then a vassal of the Ottoman Empire) was the first country in the world to have its annual crude oil output officially recorded in international statistics – 275 tonnes for 1857. In 1858, Georg Christian Konrad Hunäus found a significant amount of petroleum while drilling for lignite in Wietze, Germany. Wietze later provided about 80% of German consumption in the Wilhelmine Era. The production stopped in 1963, but Wietze has hosted a petroleum museum since 1970. Oil sands have been mined since the 18th century. In Wietze, natural asphalt/bitumen has been explored since the 18th century. Both in Pechelbronn as in Wietze, the coal industry dominated the petroleum technologies.
=== Queen's Police Medal (QPM) === England and Wales Anthony Richard Bayliss, Detective Superintendent, Warwickshire Constabulary. Frank Joseph Breen, Detective Constable, Thames Valley Police. Michael Briggs, Commander, Metropolitan Police. Eileen Margaret Eggington, Detective Chief Superintendent, Metropolitan Police. Christopher Fox, Assistant Chief Constable (designated), Warwickshire Constabulary. William Griffiths, Commander, Metropolitan Police. Gareth Jones, lately Detective Superintendent, North Wales Police. David Robertson Kenworthy, Assistant Chief Constable (designated), Avon and Somerset Constabulary. Paul Joseph Scott-Lee, Assistant Chief Constable (designated), Suffolk Constabulary. Roger John Manning, Chief Superintendent, Staffordshire Police. Graham Moore, Assistant Chief Constable (designated), Cambridgeshire Constabulary. Terence Raymond Nicholls, Constable, Metropolitan Police. Robin Edgar Norman Oake, Chief Constable, Isle of Man Constabulary. Peter John Picken, Superintendent (Divisional Commander), West Mercia Constabulary. Colin Potts, Chief Inspector (Divisional Commander), Greater Manchester Police. Gordon Michael Rogers, lately Chief Superintendent, Wiltshire Constabulary. Roger Edward Sandall, Chief Superintendent (Divisional Commander), Norfolk Constabulary. Richard Owen Thomas, Assistant Chief Constable (designated), Gwent Constabulary. Scotland Andrew Gibson Brown, Assistant Chief Constable, Lothian and Borders Police. John Orr, , Chief Constable, Strathclyde Police. William Rae, Chief Constable, Dumfries and Galloway Constabulary.
=== Russia === Russia had the most to gain from the Triple Intervention. In the preceding years, Russia had been slowly increasing its influence in the Far East since at least the Treaty of Aigun in 1858 and the building of her warm water port in Asian waters, Vladivostok. The construction of the Trans-Siberian Railway and the acquisition of another warm-water port on the China Seas would enable Russia to consolidate her presence in the region and further expand into Asia and the Pacific. Russia did not believe that the Japanese would be victorious against China in 1894. Port Arthur falling into Japanese hands would undermine its own desperate need for a warm-water port in the East.
Sources: en.wikipedia.org
The Dogras and various organisations of Hindu-majority Jammu region have demanded a separate state after bifurcation of the territory, on the basis of cultural, linguistic and religious differences from neighbouring Kashmiris (who are predominantly Muslim by faith). In 2022, only 808 Kashmiri Hindu Pandit families remained in the valley after their forced displacement by Islamic militants.
=== With phosphorus species === Thionyl chloride converts phosphonic acids and phosphonates into phosphoryl chlorides. It is for this type of reaction that thionyl chloride is listed as a Schedule 3 compound, as it can be used in the "di-di" method of producing G-series nerve agents. For example, thionyl chloride converts dimethyl methylphosphonate into methylphosphonic acid dichloride, which can be used in the production of sarin and soman.
===== Cocaine-induced midline destructive lesions ===== Cocaine-induced midline destructive lesions (CIMDL) is the progressive destruction of nasal architecture with the erosion of the palate, nasal conchae, and ethmoid sinuses associated with prolonged insufflation, colloquially 'snorting', of cocaine. Chronic intranasal usage can degrade the cartilage separating the nostrils (the septum nasi), leading eventually to its complete disappearance.
== Potential applications == A wide variety of potential applications have been envisaged. Since magnetic nanoparticles are expensive to produce, there is interest in their recycling or for highly specialized applications. The potential and versatility of magnetic chemistry arises from the fast and easy separation of the magnetic nanoparticles, eliminating tedious and costly separation processes usually applied in chemistry. Furthermore, the magnetic nanoparticles can be guided via a magnetic field to the desired location which could, for example, enable pinpoint precision in fighting cancer.
==== Tea ==== Tea contains more caffeine than coffee by dry weight. A typical serving, however, contains much less, since less of the product is used as compared to an equivalent serving of coffee. Also contributing to caffeine content are growing conditions, processing techniques, and other variables. Thus, teas contain varying amounts of caffeine. Tea contains small amounts of theobromine and slightly higher levels of theophylline than coffee. Preparation and many other factors have a significant impact on tea, and color is a poor indicator of caffeine content. Teas like the pale Japanese green tea, gyokuro, for example, contain far more caffeine than much darker teas like lapsang souchong, which has minimal caffeine content.
Sources: en.wikipedia.org
The AKC Standard requires 45–65 pounds (20–29 kg) and 21–23.5 inches (53–60 cm) at the shoulder for males, and 35–50 pounds (16–23 kg) and 19–21 inches (48–53 cm) for females. The UK Kennel Club Standard requires 51–56 centimetres (20–22 in) for males, and 46–51 centimetres (18–20 in) for females. Samoyed ears are thick and covered with fur, triangular in shape, and erect. They are almost always white but have a light to dark brown tint (known as "biscuit") to a greater or lesser extent. The tint is usually on the ears but can be visible on the whole body.
Patients with heart disease, and patients who smoked cigarettes, were less likely to survive. Another trial, the Stem Cell Transplant vs. Cyclophosphamide (SCOT) trial, is ongoing. Asengeprast is an experimental systemic scleroderma drug candidate. It is a small molecule inhibitor of the G-protein coupled receptor GPR68 with antifibrotic activity.
In the United States, when plutonium-238 became available for non-military uses, numerous applications were proposed and tested, including the cardiac pacemaker program that began on June 1, 1966, in conjunction with NUMEC. The last of these units was implanted in 1988, as lithium-powered pacemakers, which had an expected lifespan of 10 or more years without the disadvantages of radiation concerns and regulatory hurdles, made these units obsolete. As of 2007, there were nine living people with nuclear-powered pacemakers in the United States, out of an original 139 recipients. When these individuals die, the pacemaker is supposed to be removed and shipped to Los Alamos where the plutonium will be recovered. In a letter to the New England Journal of Medicine discussing a woman who received a Numec NU-5 decades ago that is continuously operating, despite an original $5,000 price tag equivalent to $36,263 in 2025 dollars, the follow-up costs have been about $19,000 ($29,502 in 2025 dollars) compared with $55,000 ($85,400 in 2025 dollars) for a battery-powered pacemaker. Another nuclear powered pacemaker was the Medtronics “Laurens-Alcatel Model 9000”. Approximately 1600 nuclear-powered cardiac pacemakers and/or battery assemblies have been located across the United States, and are eligible for recovery by the Off-Site Source Recovery Project (OSRP) Team at Los Alamos National Laboratory (LANL).
=== Lawsuits === In September 2009, the U.S. Justice Department announced that Pfizer had been ordered to pay a historic fine of $2.3 billion as a penalty for fraudulent marketing of several drugs, including Geodon. Matthew Dougherty, a 51‑year‑old former teacher and artist with a diagnosis of schizophrenia, died on May 21, 2024, at Phoenixville Hospital in Phoenixville, Pennsylvania. According to a wrongful death lawsuit filed by his family in March 2025, Dougherty had been admitted to the hospital after a mental health crisis during which he was tased by police and suffered injuries. While hospitalized, Dougherty's regular psychiatric medications were discontinued. On the evening of his death, an alarm sounded in a nearby room, causing him to become agitated. Hospital staff called the police to restrain him, and responding officers again used a taser on Dougherty. Shortly afterward, nurses administered two doses of Geodon (ziprasidone) – a total of 40 mg, an amount the lawsuit equated to "administering poison". Minutes later, Dougherty went into cardiac arrest and could not be resuscitated. The lawsuit names as defendants Tower Health, which operates Phoenixville Hospital, and seeks damages for wrongful death and negligence. At the time the suit was filed, Tower Health had not filed a response to the complaint.
Bodybuilders may supplement their diets with protein for reasons of convenience, lower cost (relative to meat and fish products), ease of preparation, and to avoid the concurrent consumption of carbohydrates and fats. Additionally, some argue that bodybuilders, by virtue of their unique training and goals, require higher-than-average quantities of protein to support maximal muscle growth. While the recommended dietary allowance is much less, Harvard Medical School points out in Harvard Health Publishing that this RDA (recommended daily allowance) is “the minimum amount you need to keep from getting sick — not the specific amount you are supposed to eat every day.” Protein supplements are sold in ready-to-drink health shakes, bars, meal replacement products (see below), bites, oats, gels and powders. Protein powders are the most popular and may have flavoring added for palatability. The powder is usually mixed with water, milk or fruit juice and is generally consumed immediately before and after exercising or in place of a meal. The sources of protein are as follows and differ in protein quality depending on their amino acid profile and digestibility:
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.